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Lanthanum carbonate: Time to 
abandon prejudices?
D Brancaccio1 and M Cozzolino1
Since lanthanum carbonate has become available there has been 
much interest in its use as a non-calcium-containing phosphate 
binder, but also much speculation among scientists about possible 
aluminum-like toxicity. This Commentary focuses on the major 
aspects of this scientific controversy, confirming the safety and 
efficacy of this new phosphate binder.
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The crucial role of phosphate in gener-
ating secondary hyperparathyroidism in 
uremic conditions, with its devastating 
clinical consequences for bone disease, 
became evident more than three decades 
ago. More recently, it has also become 
clear that high serum phosphate levels 
are associated with increased mortality, 
a fact that has been supported by large 
epidemiological studies.1 It is now evi-
dent that phosphate overload contri-
butes to accelerated vascular aging, in 
which vascular calcium deposition is a 
key factor.2 Taken together, the conclu-
sions from these major contributions 
to the literature indicate unanimously 
that strict phosphate control in dialysis 
patients should have high priority. How-
ever, reduction of dietary phosphate 
content below 900–1,000 mg per day is 
not clinically achievable and can even 
result in severe malnutrition. Therefore, 
in the large majority of dialysis patients, 
phosphate removal even with a maxi-
mized three-times-per-week dialysis 
schedule is insuffi cient to balance oral 
phosphate intake. The only therapeutic 
tool able to reach a satisfactory phos-
phate control is the use of oral phos-
phate binders.
The story of oral phosphate binders 
started at the beginning of the 1970s 
with the use of aluminum hydroxide, 
a potent phosphate binder that was at 
that time widely used for this purpose in 
dialysis patients and was unfortunately 
also often prescribed to dialysis patients 
as an antacid drug. At that time, the 
knowledge of aluminum toxicity was 
virtually zero among the scientifi c com-
munity. The clinical consequences of its 
use were understood only several years 
later. Anemia, encephalopathy, proxi-
mal myopathy, and osteomalacia repre-
sented rather common features of a slow 
progressive aluminum overload, and 
acute brain derangement leading to 
dementia was more typical of acute 
intoxication, mainly related to contami-
nated dialysis bath.
During the 1980s, calcium carbon-
ate become popular in management of 
phosphate overload in dialysis patients 
because of its combined properties 
(phosphate binding, control of meta-
bolic acidosis, calcium supplementation, 
low cost). Again, many years later, sev-
eral studies revealed the negative impact 
of high intake of calcium carbonate on 
patient survival. Importantly, Goodman 
et al.3 showed that coronary calcifi ca-
tion in dialysis patients was associated 
with increased serum phosphate and 
calcium-phosphate product levels, and 
also with the total daily calcium intake 
from calcium-containing phosphate 
binders, whereas serum calcium levels 
per se were not related to calcifi cation 
score. Several other studies have sup-
ported this concept, and it is now well 
accepted that the overuse of calcium-
containing phosphate binders may 
result in extraskeletal calcifi cation and 
increased cardiovascular mortality.
The third generation of phosphate 
binders was introduced at the beginning 
of the 1990s. Sevelamer hydrochloride 
was the fi rst aluminum- and calcium-
free phosphate binder, containing a 
hydrogel of cross-linked poly(allylamine 
hydrochloride). Sevelamer binds phos-
phate anions through ionic exchange 
with chloride. Treatment of dialysis 
patients with sevelamer, in compari-
son with calcium carbonate, slowed 
down the progression of coronary and 
aortic calcifi cation in a prospective ran-
domized study in which the calcifi cation 
score was assessed in basal conditions 
and after 1 year of treatment.4 In addi-
tion to its phosphate-binding capacity, 
sevelamer also acts as a bile acid seques-
trant, signifi cantly lowering total and 
low-density lipoprotein cholesterol.
More recently, lanthanum carbon-
ate became available as a phosphate 
binder. There has been much enthusi-
asm for this agent, but also much con-
cern among the physicians involved 
in clinical management of  uremic 
patients about potential aluminum-like 
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toxicities because of lanthanum’s sup-
posed chemical similarities to alumi-
num. Common questions have been:
(1) Is it possible that in the future we 
will observe some important side effects 
from the use of lanthanum, as we did 
previously for aluminum?
(2) Considering that lanthanum 
deposits primarily in the liver, should 
we expect in the long run a form of liver 
derangement and failure?
(3) The lesson from aluminum 
encephalopathy taught us that even with 
mild elevation of serum aluminum lev-
els, neurological derangement could be 
observed. Could this be the case also for 
lanthanum?
In addressing this series of questions 
rationally, there are some preliminary 
considerations: 
(1) Not all trace elements are the same. 
The only realistic analogy between alu-
minum and lanthanum is their strong 
affi nity to bind inorganic phosphorus.
(2) Tissue deposition does not neces-
sarily mean toxicity. In fact, aluminum 
is a typical example of this. After oral 
administration, it is heavily deposited in 
the liver, where toxicity has never been 
observed, while a minimal increase in the 
brain can be responsible for important 
neurological derangement.5
(3) Again, for separating the two con-
cepts of tissue deposition and intoxica-
tion, another example is chromium, 
which accumulates heavily in the serum 
and bone of patients on dialysis with-
out any identifi ed clinical correlate.6 It 
should be remembered that bone and 
liver are involved in the sequestration or 
transport of many metals. This explains 
why these organs are naturally exposed 
to a greater extent than other tissues 
or organs. In other words, trace metals 
have distinct tissue-specifi c biological 
actions and toxicities, and it is incorrect 
to extrapolate data between unrelated 
metals and different tissues.
Indeed, aluminum and lanthanum 
have different structures and metabo-
lism. More specifi cally, lanthanum is 
the most cationic element of the rare-
earth group, is in a trivalent form, and 
has important avidity toward carboxyl 
and phosphate groups. Lanthanum 
carbonate is considered the most active 
phosphate binder among the rare-
earth metals, with an affi nity toward 
phosphate similar to that of aluminum 
hydroxide. However, the two metals 
have very different metabolic behaviors 
that explain why aluminum accumu-
lates in the bodies of uremic patients 
whereas lanthanum does not. Alumi-
num is excreted by the kidneys, whereas 
lanthanum has a biliary excretion.
Lanthanum and the bone
A large number of studies have been 
dedicated to determining the deposi-
tion of lanthanum in bone just because 
of the memory of aluminum-induced 
osteomalacia, a common complica-
tion of aluminum overload in dialysis 
patients. Whereas aluminum is observ-
able mainly at the mineralization 
front, lanthanum in bone in any form 
of renal osteodystrophy is observed 
both in active and in quiescent sites of 
bone mineralization and is also distrib-
uted diffusely in the mineralized bone 
matrix. In addition, whereas the lantha-
num–calcium ratio of 1:2,000 in bone 
is negligible, the ratio of aluminum 
to calcium is much higher at 1:15.7 A 
prospective randomized open-label 
study, in which two groups of dialysis 
patients received lanthanum carbonate 
or CaCO3 for 1 year, addressed the possi-
ble development of aluminum-like bone 
disease. Bone biopsies, performed in 63 
patients in basal conditions and after 
1 year of therapy, showed an increase 
of adynamic bone disease or a wors-
ening of their hyperparathyroidism in 
those who were taking CaCO3, whereas 
those treated with lanthanum carbonate 
showed a reduction of the extreme form 
of osteodystrophy. Concomitantly, after 
1 year of treatment, serum lanthanum 
levels reached a plateau within 12 weeks 
of treatment and bone levels were below 
5.5 µg per wet weight.8
Lanthanum and the liver
Lanthanum deposition in the liver still 
represents an important issue because 
of its elevated concentration. However, 
even heavy forced oral loading in rats 
receiving 2,000 mg per kg per day did 
not increase liver concentration higher 
than 3.5 µg per g. Lanthanum was 
found in lysosomes at the biliary pole 
of the hepatocyte and within the bile 
canalicula9 but not in mitochondria, 
nuclei, or cytoplasm; this indicates that 
its presence in the lysosomes represents 
an excretory process, in analogy to other 
Figure 1 | Ultrastructure of the blood–brain barrier in the developing corpus callosum in 
postnatal rat brain: evaluation of the lanthanum deposition after La(NO3)3 infusion, using 
electron-dense tracers. AS, astrocyte; BL, basal lamina; P, pericyte. (Adapted from ref. 13.)
P
Lanthanum  on
luminal surface
Lanthanum in 
intercellular space
blocked at tight 
junction
P-pericyte; BL - basal lamina; -astrocyteAS
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lysosomally transported metals such as 
iron and copper10 whose natural concen-
trations are up to 2,000 and 5.5 p.p.m., 
respectively. Finally, it should be consid-
ered that in a recent analysis of a large 
series of patients participating in a phase 
III trial in which lanthanum carbonate 
was given at doses up to 3.75 g per day for 
up to 3 years, no increase of liver enzyme 
activities was observed, nor any effect 
related to hepatobiliary adverse events.11
Lanthanum and the brain
Altmann et al.12 (this issue) present 
data collected in 360 dialysis patients, 
divided into two groups receiving lan-
thanum carbonate versus standard ther-
apy, in a randomized multicenter study 
comparing their cognitive function over 
a 2-year period. Th is open-label study 
was designed to answer the important 
question of whether lanthanum carbon-
ate might accelerate the natural dete-
rioration in cognitive function seen in 
dialysis patients.
Dr. Altmann is an expert in dialy-
sis encephalopathy and its evaluation. 
He and his colleagues published an 
important paper many years ago dur-
ing the aluminum era5 in which they 
showed that cerebral dysfunction can 
be observed in hemodialysis patients 
even without overt aluminum toxicity. 
At that time it became clear also that 
a small increase of serum aluminum, 
and presumably of aluminum in the 
brain, could be followed by neurological 
derangement. Dr. Altmann has excellent 
credentials for studying this same issue 
with the use of lanthanum.
The core messages of the present 
paper by Altmann et al.12 are clear: 
(1) all patients on dialysis treatment 
present a neurological deterioration in 
the long run; (2) this deterioration can 
be observed in any patient independ-
ently of the phosphate-binder therapy 
used; and (3) this neurological dete-
rioration is not exacerbated by lantha-
num treatment. This confi rms previous 
studies performed in animals exposed 
to large doses of lanthanum carbonate 
in which it has been shown that lantha-
num ions cannot pass between the tight 
junctions of the blood–brain barrier 
(Figure 1).13
In sum, lanthanum carbonate is effec-
tive in lowering serum phosphate levels 
in patients on dialysis, and it appears to 
be safe with respect to bone disease, liver 
toxicity, and now cognitive function. It 
is a useful and important addition to 
our armamentarium in the manage-
ment of dialysis patients. Altmann et 
al.12 conclude their paper by stating 
that lanthanum carbonate is effective 
and well tolerated for the treatment of 
patients with hyperphosphatemia in 
Stage 5 chronic kidney disease. How-
ever, common sense would suggest its 
use at any stage of Chronic Renal Failure 
when serum phosphate levels cannot be 
controlled by a low-phosphorus diet.
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